New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:41 EDTANIPANI Pharmaceuticals fundamentals appear on track, says Roth Capital
After ANI's stock came under considerable pressure, Roth Capital spoke with the company's management and thinks the company's fundamentals remain on track. The firm believes that the company's revenue and EPS could beat expectations, and it reiterates a Buy rating on the stock.
News For ANIP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
08:13 EDTANIPANI acquires exclusive rights to distribute three generics from H2 Pharma
ANI Pharmaceuticals announced that it has acquired the exclusive rights to distribute 1% and 2.5% hydrocortisone cream for rectal use and the exclusive rights to distribute the authorized generic of Lipofen from H2-Pharma, LLC for $10M. In addition, ANI also acquired an early stage development project for an undisclosed generic injectable drug product.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use